title: Management of AML: who do we really cure?
abstract: Most clinicians caring for patients with AML do not use the word "cure" casually, since for many patients diagnosed with AML, a state of cure or even of long term survival remains elusive. Analysis of prognostic factors may aid in defining the chance for cure in various AML subtypes, and improvements are required at all stages of AML treatment if cure is to be realized in a higher proportion of patients. In order to improve outcome, requirements will include targeting the mutation responsible for the leukemia emergence, suppressing the stem or progenitor cell which acquires the mutation, and the capability to deliver therapy to patients who themselves have adverse co-morbidities.
authors.affiliation: Hematology/Oncology, JP Wilmot Cancer Center, University of Rochester Medical Center/Strong Memorial Hospital, Rochester, NY 14642, USA. jane_liesveld@urmc.rochester.edu
authors.forename: Jane
authors.initials: J
authors.lastname: Liesveld
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019468:Disease Management; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D058990:Molecular Targeted Therapy; D018365:Neoplasm, Residual; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D016896:Treatment Outcome